Tumors That Acquire Resistance to Low-dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide

Overview

Journal Neoplasia

Publisher Elsevier

Specialty Oncology

Date 2011 Jan 20

PMID 21245939

Citations 29

Authors

Urban Emmenegger

Giulio Francia

Annabelle Chow

Yuval Shaked

Andrew Kouri

Shan Man

Robert S Kerbel

Affiliations

Soon will be listed here.

Abstract

Low-dose metronomic (LDM) chemotherapy is emerging as an alternative or supplemental dosing strategy to conventional maximum tolerated dose (MTD) chemotherapy. It is characterized primarily, but not exclusively, by antiangiogenic mechanisms of action and the absence of high-grade adverse effects commonly seen with MTD chemotherapy. However, similar to other anticancer therapies, inherent resistance to LDM chemotherapy is common. Moreover, even tumors that initially respond to metronomic regimens eventually develop resistance through mechanisms that are as yet unknown. Thus, we have developed in vivo models of PC-3 human prostate cancer cells resistant to extended LDM cyclophosphamide therapy. Such PC-3 variants show stable resistance to LDM cyclophosphamide in vivo yet retain in vitro sensitivity to 4-hydroperoxy-cyclophosphamide (precursor of the active cyclophosphamide metabolite 4-hydroxy-cyclophosphamide) and other chemotherapeutic agents, namely, docetaxel and doxorubicin. Moreover, LDM cyclophosphamide-resistant PC-3 variants remain sensitive to MTD cyclophosphamide therapy in vivo. Conversely, PC-3 variants made resistant in vivo to MTD cyclophosphamide show varying levels of resistance to metronomic cyclophosphamide when grown in mice. These results and additional studies of variants of the breast cancer cell line MDA-MB-231 suggest that resistance to LDM cyclophosphamide is a distinct phenomenon from resistance to MTD cyclophosphamide and that LDM cyclophosphamide administration does not select for MTD chemotherapy resistance. As such, our findings have various implications for the clinical use of metronomic chemotherapy.

Citing Articles

Immunogenicity of an adjuvanted broadly active influenza vaccine in immunocompromised and diverse populations.

Hendy D, Pena E, Ontiveros-Padilla L, Dixon T, Middleton D, Williamson G Bioeng Transl Med. 2024; 9(2):e10634.

PMID: 38435811 PMC: 10905549. DOI: 10.1002/btm2.10634.

Cyclic Metronomic Chemotherapy for Pediatric Tumors: Six Case Reports and a Review of the Literature.

Carcamo B, Francia G J Clin Med. 2022; 11(10).

PMID: 35628975 PMC: 9144744. DOI: 10.3390/jcm11102849.

N-of-1 Healthcare: Challenges and Prospects for the Future of Personalized Medicine.

You K, Wang P, Ho D Front Digit Health. 2022; 4:830656.

PMID: 35224536 PMC: 8873079. DOI: 10.3389/fdgth.2022.830656.

One method to establish Epstein-Barr virus-associated NK/T cell lymphoma mouse models.

Xue W, Li W, Shang Y, Zhang Y, Lan X, Wang G J Cell Mol Med. 2018; 23(2):1509-1516.

PMID: 30484952 PMC: 6349153. DOI: 10.1111/jcmm.14057.

Is There an Opportunity for Current Chemotherapeutics to Up-regulate MIC-A/B Ligands?.

Quirk K, Ganapathy-Kanniappan S Front Pharmacol. 2017; 8:732.

PMID: 29089892 PMC: 5651020. DOI: 10.3389/fphar.2017.00732.

References

Man S, Bocci G, Francia G, Green S, Jothy S, Hanahan D . Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 2002; 62(10):2731-5. View

Bristow R, Hill R . Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer. 2008; 8(3):180-92. DOI: 10.1038/nrc2344. View

Emmenegger U, Kerbel R . Five years of clinical experience with metronomic chemotherapy: achievements and perspectives. Onkologie. 2007; 30(12):606-8. DOI: 10.1159/000111479. View

Sobrero A, Aschele C, Bertino J . Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation. J Clin Oncol. 1997; 15(1):368-81. DOI: 10.1200/JCO.1997.15.1.368. View

Bergers G, Hanahan D . Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008; 8(8):592-603. PMC: 2874834. DOI: 10.1038/nrc2442. View

Zhang J, Tian Q, Chan S, Duan W, Zhou S . Insights into oxazaphosphorine resistance and possible approaches to its circumvention. Drug Resist Updat. 2005; 8(5):271-97. DOI: 10.1016/j.drup.2005.08.003. View

Kerbel R . Tumor angiogenesis. N Engl J Med. 2008; 358(19):2039-49. PMC: 4542009. DOI: 10.1056/NEJMra0706596. View

Grothey A, Galanis E . Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol. 2009; 6(9):507-18. DOI: 10.1038/nrclinonc.2009.110. View

Shaked Y, Ciarrocchi A, Franco M, Lee C, Man S, Cheung A . Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science. 2006; 313(5794):1785-7. DOI: 10.1126/science.1127592. View

10.

Perry J, Belanger K, Mason W, Fulton D, Kavan P, Easaw J . Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010; 28(12):2051-7. DOI: 10.1200/JCO.2009.26.5520. View

11.

Klement G, Huang P, Mayer B, Green S, Man S, Bohlen P . Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res. 2002; 8(1):221-32. View

12.

Emmenegger U, Man S, Shaked Y, Francia G, Wong J, Hicklin D . A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res. 2004; 64(11):3994-4000. DOI: 10.1158/0008-5472.CAN-04-0580. View

13.

Reichle A, Vogt T . Systems biology: a therapeutic target for tumor therapy. Cancer Microenviron. 2009; 1(1):159-70. PMC: 2654356. DOI: 10.1007/s12307-008-0012-5. View

14.

Kerbel R, Kobayashi H, Graham C . Intrinsic or acquired drug resistance and metastasis: are they linked phenotypes?. J Cell Biochem. 1994; 56(1):37-47. DOI: 10.1002/jcb.240560108. View

15.

Watanabe T, Sano M, Takashima S, Kitaya T, Tokuda Y, Yoshimoto M . Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial. J Clin Oncol. 2009; 27(9):1368-74. DOI: 10.1200/JCO.2008.18.3939. View

16.

Emmenegger U, Morton G, Francia G, Shaked Y, Franco M, Weinerman A . Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res. 2006; 66(3):1664-74. DOI: 10.1158/0008-5472.CAN-05-2598. View

17.

Cardoso F, Senkus-Konefka E, Fallowfield L, Costa A, Castiglione M . Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v15-9. DOI: 10.1093/annonc/mdq160. View

18.

Price K, Goldhirsch A . Clinical trial update: International Breast Cancer Study Group. Breast Cancer Res. 2005; 7(6):252-4. PMC: 1410774. DOI: 10.1186/bcr1334. View

19.

Thoenes L, Hoehn M, Kashirin R, Ogris M, Arnold G, Wagner E . In vivo chemoresistance of prostate cancer in metronomic cyclophosphamide therapy. J Proteomics. 2010; 73(7):1342-54. DOI: 10.1016/j.jprot.2010.02.019. View

20.

Pietras K, Hanahan D . A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol. 2004; 23(5):939-52. DOI: 10.1200/JCO.2005.07.093. View